lipoprotein metabolism - genetics Flashcards
lipoprotein particle responsible for cholesterol-CAD association
LDL
lipoprotein particle responsible for TG-CAD association
remnants from VLDL or chylomicron
lipid levels are __% genetic, __% non-genetic
60% genetic
40% non-genetic
FH (familial hypercholesterolemia)
-aka
-symptoms
-abnormal lipids
-abnormal lipoproteins
-inheritance pattern
-mutations
(type IIa hyperlipoproteinemia)
atherosclerosis, early MI, xanthoma, lipid deposits in skin
hypercholesterolemia
elevated LDL
monogenic, autosomal co-dominant
LOF in LDLR, APOB
GOF in PCSK9
familial chylomicronemia
-aka
-symptoms
-abnormal lipids
-abnormal lipoproteins
-inheritance pattern
-mutations
(type I hyperlipoproteinemia)
pancreatitis, eruptive xanthomas
hypertriglyceridemia
chylomicronemia
monogenic, autosomal recessive
LOF in LPL, APOC2
familial dysbetalipoproteinemia
-aka
-symptoms
-abnormal lipids
-abnormal lipoproteins
-inheritance patterns
-mutations
(type III hyperlipoproteinemia)
early heart disease, xanthomas, pancreatitis
hyperTG & hyperchol
elevated IDL / CMR
autosomal recessive (90%)
LOF in APOE E2
autosomal dominant (10%)
LOF in APOE
FHBL (familial hypobetalipoproteinemia)
-symptoms
-abnormal lipids
-abnormal lipoproteins
-inheritance pattern
-mutations
fatty liver, steatorrhea, cirrhosis
low TG, cholesterol
low VLDL / CM
monogenic, autosomal dominant
truncating in APOB
LOF in PCSK9
ABL (abetalipoproteinemia)
-symptoms
-abnormal lipids
-abnormal lipoproteins
-inheritance pattern
-mutations
fatty liver, steatorrhea, neurological disorders, night blindness
low TG, cholesterol
absent VLDL / CM
monogenic, autosomal recessive
LOF in MTTP
familial HDL deficiency
-aka
-symptoms
-abnormal lipids
-abnormal lipoproteins
-inheritance pattern
-mutations
(Tangier disease)
enlarged orange tonsils
lipids normal
low / absent HDL
monogenic, autosomal recessive
LOF in ABCA1 [impaired reverse cholesterol transport]
statin drugs mechanism of action for lowering cholesterol
inhibits HMGCR (rate-limiting enzyme for cholesterol synthesis)
decreases LDL
PCSK9 inhibitor drugs mechanism of action for lowering cholesterol
inhibits PCSK9
->
more LDLR on cell surface
->
more LDL uptake (so less LDL in blood)